首页 | 本学科首页   官方微博 | 高级检索  
     


Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post‐transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study
Authors:Raffaella Lionetti  Vincenza Calvaruso  Paola Piccolo  Rossella Letizia Mancusi  Chiara Mazzarelli  Stefano Fagiuoli  Marzia Montalbano  Ilaria Lenci  Paola Carrai  Giovanni Guaraldi  Ubaldo Visco‐Comandini  Martina Milana  Marco Biolato  Laura Loiacono  Giovanna Valente  Antonio Craxì  Mario Angelico  Gianpiero D'offizi
Affiliation:1. Infectious and Liver Diseases, Lazzaro Spallanzani National Infectious Disease Institute, Rome, Italy;2. Gastroenterology Unit, University of Palermo, Palermo, Italy;3. Department of Internal Medicine, San Giovanni Calibita Fatebenefratelli Hospital, Rome, Italy;4. Hepatology Unit, Tor Vergata University, Rome, Italy;5. Consortium for Economic Research in Health (CREA Sanità), Tor Vergata University, Rome, Italy;6. Gastroenterology and Liver Unit, Niguarda Ca’ Granda Hospital, Milan, Italy;7. Gastroenterology and Liver Unit, San Giovanni XXIII Hospital, Bergamo, Italy;8. Liver Transplantation Unit, Pisa Hospital, Pisa, Italy;9. Infectious Diseases Unit, University of Modena, Modena, Italy;10. Liver Transplant Medicine, Fondazione Policlinico Gemelli Catholic University, Rome, Italy;11. Gastroenterology Unit, San Sebastiano Hospital, Caserta, Italy
Abstract:
Keywords:antiviral treatment  cirrhosis  direct antiviral agents  hepatitis C virus  liver transplantation
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号